{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-046163","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.807244+00:00","generated_at":"2026-06-07T06:55:00.671759+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Biosciences enters exchange agreements for Series F-1 Preferred Stock in connection with Aditxt merger","bullets":["Evofem exchanged certain rights and warrants with holders for 22,280 shares of new Series F-1 Convertible Preferred Stock.","The exchange agreements were executed on Dec 21, 2023, following the merger agreement with Aditxt signed on Dec 11, 2023.","Holders agreed to waive change of control redemption rights related to the merger in exchange for new rights and preferred stock.","The Series F-1 Preferred Stock will later be exchanged for Aditxt preferred stock prior to merger consummation.","The exchange was exempt from registration under Section 3(a)(9) of the Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-046163","json":"https://secwatch.observer/filing/0001493152-23-046163.json","markdown":"https://secwatch.observer/filing/0001493152-23-046163.md","text":"https://secwatch.observer/filing/0001493152-23-046163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223046163/0001493152-23-046163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223046163/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:55:00.671759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c631c780078f01b168c2bab2594fc644285e8ae9","claim":"Evofem Biosciences, Inc. entered into Rights Exchange Agreement with Holders of previously issued Securities valued at Exchange of Original Rights for New Rights (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, Evofem Biosciences, Inc. (the “Company”) entered into the following agreements with holders (each a “Holder”) of certain of the Company’s previously issued Securities (as defined below) (i) a waiver and rights exchange agreement (the “Rights Exchange Agreements\")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223046163/0001493152-23-046163-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Holders of previously issued Securities"},{"label":"Value","value":"Exchange of Original Rights for New Rights"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}